

Investor Presentation

Advanced Imaging. Accessible Care.



Disclaimer

This document including links to press releases, presentations, fact sheets, and/or corporate materials including audio and video files either linked or imbedded, may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing on this website or its documents should be deemed to be medical or other advice of any kind.

Izotropic Corporation holds the exclusive global licensing rights to breast CT technology from the Regents of the University of California. This technology was originally developed at the University of California, Davis, under the Breast Tomography Project led by Company Director Dr. John Boone and his clinical collaborators. Four successive breast CT research devices were developed and evaluated at UC Davis. The clinical data and images referenced by the Company were generated using these research prototypes. IzoView, the commercial breast CT system developed by Izotropic Corporation, is a distinct and separate device designed for commercial use and was not used to generate this data or these images. Accordingly, any clinical performance data or images referenced by the Company should not be interpreted as evidence of IzoView's abilities, safety or effectiveness. IzoView remains an investigational device and has not been evaluated in clinical trials or studies to support claims of diagnostic performance. No assurances are made that results achieved with earlier breast CT systems will be replicated with IzoView. The Company makes no claims or guarantees regarding the diagnostic capabilities, clinical benefits, or regulatory approval of IzoView at this time. IzoView has not been approved or cleared by any regulatory authority and is not yet available for commercial sale. Any statements regarding potential clinical utility are for informational purposes only.

Podcast episodes including translations are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources.

All images are for illustrative purposes only.

Company Overview



- Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, targeting unmet needs in breast cancer care.
- IzoView is a fully engineered, pre-commercial medical imaging device designed to overcome the limitations of mammography, DBT, ultrasound, and MRI, particularly in women with dense breast tissue.
- FDA-aligned pivotal clinical study design, entering final regulatory stages, raising funds to run study and commercialize.
- Publicly traded on CSE: **IZO**, OTCQB: **IZOZF**, and FSE: **1R3**.



Why Now?



- Breast cancer is the most commonly diagnosed cancer in women globally, with 2.3M+ new cases/year¹.
- 315,000+ new cases expected in the U.S. in 2025².
- Current technologies fail 50%+ of women with dense breasts³.
- U.S. regulatory mandates for breast density disclosure in mammography reports are now in effect⁴.
- 38 U.S. states require insurance coverage for supplemental screening in women with dense breasts⁵.
- Imaging centers face rising pressure to improve diagnostic accuracy, streamline workflows, and integrate AI.

1. (2024, March 13). Breast cancer. World Health Organization. Retrieved February 1, 2025, from <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
2. (2025, May 5). Key Statistics for Breast Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html>
3. (2024, December 9). Dense Breasts: Answers to Commonly Asked Questions. National Cancer Institute. Retrieved July 24, 2025, from <https://www.cancer.gov/types/breast/breast-changes/dense-breasts>
4. (2023, March 9). FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight. U.S. Food and Drug Administration. Retrieved January 7, 2025, from <https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance>
5. (2025, June 4). Expanded Breast Imaging Insurance Coverage by State. DenseBreast-Info.org. Retrieved July 30, 2025, from <https://densebreast-info.org/wp-content/uploads/2025/06/DBI-INSURANCE-TABLE060425.pdf>

The Global Market Opportunity



Breast Imaging is a High-Growth, High-Need Market.

- Global breast imaging device market to grow from \$5.4B in 2024 to \$8.7B in 2030 (CAGR 8.25%)¹.
- U.S. market projected to reach \$1.55B by 2030² (CAGR 7.57%).
- Dense breast patients represent ~50% of women- a structurally underserved segment.
- Over 43M annual mammography procedures in the U.S.³.
- Estimated USD \$8B spent annually in the U.S. on follow-up imaging and diagnostic procedure costs after initial mammography screening⁴.

1. (2025). Breast Imaging Market Global Forecast 2025-2030. 360i Research.

2. (2025). Breast Imaging Market Global Forecast 2025-2030. 360i Research.

3. (2025, March 18). MQSA National Statistics. U.S. Food & Drug Administration. <https://www.fda.gov/radiation-emitting-products/mammography-information-patients/mqsa-national-statistics>

4. Vlahiotis A, Griffin B, Stavros AT, Margolis J. Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. Clinicoecon Outcomes Res. 2018;10:157-167 <https://doi.org/10.2147/CEOR.S150260>

Mammography & Digital Breast Tomosynthesis (DBT)



Unmet Clinical Need

- Mammography misses ~20% of cancers present at the time of screening¹.
- Compression-based 2D imaging (mammography and digital breast tomosynthesis) can hide breast cancers in dense tissue, as both dense tissue and cancers appear white on imaging.
- MRI, while highly sensitive, is expensive, time-consuming, and limited in accessibility.
- High false positive rates, repeat appointments, and unnecessary biopsies remain widespread.
- Clinical guidelines and reimbursement policies are shifting to support advanced supplemental imaging.

MRI



1. (2023, February 21). Mammograms. National Cancer Institute. Retrieved July 16, 2025, from <https://www.cancer.gov/types/breast/mammograms-fact-sheet>


IzoView Breast CT

No Compression. No delays. Just Answers.


- Purpose-built CT imaging system delivering true 3D breast images in ~10 seconds- without compression or breast handling.
- Fully self-shielded radiation system, installable in standard rooms, including outpatient clinics and mobile units.
- Spatial resolution 100x greater than MRI.
- Positioned to bridge the gap in between DBT and MRI.
- Fully engineered and tested; readying for clinical study deployment.
- Strong IP and trade secret position.



[Watch the IzoView Scan Experience here](#)



Technical & Clinical Validation



- Based on NIH-funded technology licensed from the Regents of the University of California (UC Davis), validated in 4 successive prototypes, clinical trials have imaged hundreds of women and produced 50+ publications.
- Contrast-enhanced breast CT at UC Davis routinely images tumors 2mm in size¹. Average sized tumor imaged on mammography is 11mm².
 - Equates to 1 - 1.25 years earlier detection. Risk of death increases by 10% for every month cancer treatment is delayed³.
- Studies^{4,5} have shown that:
 - Malignant (cancerous) masses better visualized on contrast-enhanced breast CT than with digital mammography or DBT.
 - Malignant micro-calcifications are equally conspicuous on all three modalities.
 - Benign (non-cancerous) calcifications were better visualized by digital mammography and DBT than with contrast-enhanced breast CT.
 - No performance differences were found for benign masses on all three modalities.
 - Breast CT would be more practical and cost-effective than breast MRI in a breast imaging clinic.

All images are of the same breast. Images are from prototype devices. Images were not produced using IzoView.

1. [Izotronic Corporation]. (2023, March 6). Micro-calcifications, Smaller Cancers, Biopsies & more with Breast CT! [Video]. <https://www.Youtube.com>. https://youtu.be/_lp7xErSWgA?si=b9GBAekib6wPokVn


2. Eldridge, L. E. M., MD, & Paul, D., MD (2024, September 19). How Fast Does Breast Cancer Start, Grow, and Spread? VeryWellHealth. Retrieved December 6, 2024, from <https://www.verywellhealth.com/breast-cancer-growth-rate-4175666>

3. (2020, April 11). Every month delayed in cancer treatment can raise risk of death by around 10%. BMJ Group. Retrieved December 2, 2024, from <https://bmjgroup.com/every-month-delayed-in-cancer-treatment-can-raise-risk-of-death-by-around-10/>

4. Aminololama-Shakeri S, Abbey CK, López JE, Hernandez AM, Gazi P, Boone JM, Lindfors KK. Conspicuity of suspicious breast lesions on contrast enhanced breast CT compared to digital breast tomosynthesis and mammography. Br J Radiol. 2019 May;92(1097):20181034. doi: 10.1259/bjr.20181034. Epub 2019 Apr 3. PMID: 30810339; PMCID: PMC6580915.

5. Boone JM, Kwan AL, Yang K, Burkett GW, Lindfors KK, Nelson TR. Computed tomography for imaging the breast. J Mammary Gland Biol Neoplasia. 2006 Apr;11(2):103-11. doi: 10.1007/s10911-006-9017-1. PMID: 17053979.

Near-Term Milestones & Catalysts



- Complete funding to execute next phase of commercialization plans.
- Announce hospital partners for FDA clinical study sites and IzoView clinical research locations.
- Build, ship, and install IzoView devices at partner hospitals.
- Initiate clinical study, image first patients.
- Announce new product developments.
- Secure LOIs and documented IzoView pre-sales commitments from early adopter sites to establish an installation pipeline.

Market Info & Comparables



NASDAQ: HOLX



NASDAQ: NNOX



NASDAQ: ICAD
(Acquired June 2025)



NYSE: BLFY




NASDAQ: LNTH


- Trading around \$65/share, Hologic transformed breast cancer screening by being the first to commercialize digital breast tomosynthesis (DBT), taking digital mammography from 2D to 15-degree imaging.
- Trading around \$4.60/share, Nano-x repositioned an outdated baggage scanning x-ray technology for low-cost decentralized imaging markets.
- Trading around \$1.40/share, Butterfly Network launched a general-purpose ultrasound device focused on portability.
- Trading around \$3.80/share when acquired by RadNet in a transaction valued at USD \$103M, iCAD was one of the first to bring AI software to mammography.
- Trading near \$72/share, Lantheus began as a radiopharmaceutical provider and expanded into precision diagnostics through strategic acquisitions.

Links

Website



Videos



News

Izotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and Forecast

- Company listed in Research and Markets' announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market-

- "U.S. breast cancer screening and diagnostic [device] market was valued at \$1.55 billion in 2024 and is anticipated to reach \$2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-2030".

Team



Podcast



BreastCT.com





Advanced Imaging. Accessible Care.

ir@izocorp.com | info@izocorp.com
1-833-IZO-CORP

WWW.IZOCORP.COM
OTCQB: IZOZF | CSE: IZO